SCHEMBL26429397

SCHEMBL26429397

COc1ccc2nc(N3C[C@@H](C)N(C(=O)OC4CC5(C4)CN(Cc4ccccc4)C5)C[C@@H]3C)cnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.41
GHSR Q92847 1/20 0.38
KCNH2 Q12809 1/20 0.37
HCRTR1 O43613 2/20 0.36
HCRTR2 O43614 2/20 0.36
HDAC1 Q13547 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
HPGDS O60760 1/20 0.34
CCR8 P51685 1/20 0.34
MAPK14 Q16539 2/20 0.34
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34
KIT P10721 1/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26429456 1.00 HCAR2 (0.41) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL30345594 1.00 HCAR2 (0.41) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL30345588 1.00 HCAR2 (0.41) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL26429701 0.93 CYP2C9 (0.36) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL26429665 0.93 CCR1 (0.36) HCAR2KCNH2HCRTR1HCRTR2KDM4E
SCHEMBL26429683 0.91 CHEK2 (0.39) HCAR2HPGDS
SCHEMBL26429430 0.91 HCAR2 (0.49) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL26429431 0.91 HCAR2 (0.49) HCAR2GHSRKCNH2HCRTR1HCRTR2
SCHEMBL26429607 0.90 HCAR2 (0.41) HCAR2HCRTR1HCRTR2HDAC1CYP2D6
SCHEMBL23744486 0.89 HCAR2 (0.42) HCAR2KCNH2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP claimed
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 HCAR2 76/4885GHSR 288/4885KCNH2 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.